Paricalcitol for reduction of albuminuria in diabetes [1]

The Lancet

Volumn 377, Issue 9766, 2011, Pages 635-

  Delanaye, Pierre ^a   Mariat, Christophe ^b   Krzesinski, Jean Marie ^a   Cavalier, Etienne ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; PARICALCITOL; PLACEBO; BONE DENSITY CONSERVATION AGENT; ERGOCALCIFEROL;

ALBUMINURIA; DIABETES MELLITUS; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN URINE LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; NOTE; TREATMENT OUTCOME; URINE; VITAMIN D DEFICIENCY; VITAMIN D RESPONSIVE ELEMENT;

ALBUMINURIA; BONE DENSITY CONSERVATION AGENTS; CREATININE; DIABETIC NEPHROPATHIES; ERGOCALCIFEROLS; HUMANS; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN D RESPONSE ELEMENT;

EID: 79951800580     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(11)60222-5     Document Type: Letter

References (5)

1. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-51.
2. Houillier P, Coste J, Froissart M. How many measurements to make a decision? Clin J Am Soc Nephrol 2010; 5: 1161-62.
3. Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC. Vitamin D: current status and perspectives. Clin Chem Lab Med 2009; 47: 120-27.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD). Kidney Int Suppl 2009; 113: S1-130.
5. Thomas MC, Cooper MA. Into the light? Diabetic nephropathy and vitamin D. Lancet 2010; 376: 1521-22.